Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: Its efficacy in relation to gender and previous radio therapy

European Journal of Endocrinology

Volumn 160, Issue 4, 2009, Pages 535-542

  Marazuela, Mǒnica ^a   Lucas, Tomś ^b   Alvarez Escol, Cristina ^c   Puig Domingo, Manel ^d   de La Torre, Nuria Garcia ^e   de Miguel Novoa, Paz ^e   Duran Hervada, Alejandra ^e   Manzanares, Rafael ^a   Laque Ramírez, Manuel ^a   Halperin, Irene ^d   Casanueva, Felipe F ^f,g   Bernabeu, Ignacio ^f  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; GROWTH HORMONE; HEMOGLOBIN A1C; INSULIN; OCTREOTIDE; ORAL ANTIDIABETIC AGENT; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; DRUG DERIVATIVE; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; RECOMBINANT PROTEIN; SOMATOSTATIN;

ACROMEGALY; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE METABOLISM; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INSULIN TREATMENT; LIPOHYPERTROPHY; LIVER DYSFUNCTION; LIVER FUNCTION; LONG TERM CARE; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SIDE EFFECT; SPAIN; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; DRUG ANTAGONISM; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; SEXUAL DEVELOPMENT;

ACROMEGALY; ADOLESCENT; ADULT; AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG RESISTANCE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LONG-TERM CARE; MALE; MIDDLE AGED; RECEPTORS, SOMATOTROPIN; RECOMBINANT PROTEINS; SEX CHARACTERISTICS; SOMATOSTATIN; YOUNG ADULT;

EID: 64549096004     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0705     Document Type: Article

References (30)

1. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ & Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology 1994 41 95-102.
2. Freda PU, Wardlaw SL & Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. Journal of Neurosurgery 1998 89 353-358.
3. Stewart PM. Pegvisomant: an advance in clinical efficacy in acromegaly. European Journal of Endocrinology 2003 148 S27-S32.
4. Stewart PM. Current therapy for acromegaly. Trends in Endocrinology and Metabolism 2000 11 128-132.
5. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C & Beckers A. Cabergoline in the treatment of acromegaly: a study in 64 patients. Journal of Clinical Endocrinology and Metabolism 1998 83 374-378.
6. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S & Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 4465-4473.
7. Kopchick JJ, Parkinson C, Stevens EC & Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Reviews 2002 23 623-646.
8. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
9. Parkinson C, Burman P, Messig M & Trainer PJ. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2007 92 190-195.
10. Herman-Bonert VS, Zib K, Scarlett JA & Melmed S. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism 2000 85 2958-2961.
11. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ & Lombardi G. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology 2006 154 467-477.
12. Colao A, Pivonello R, Cappabianca P, Auriemma RS, De Martino MC, Ciccarelli A, de Divitiis E & Lombardi G. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs. Journal of Endocrinological Investigation 2003 26 53-56.
13. Drake WM, Parkinson C, Akker SA, Monson JP, Besser GM & Trainer PJ. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. European Journal of Endocrinology 2001 145 451-456.
14. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B & Strasburger CJ. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology 2007 156 75-82.
15. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529.
16. DiChiro G & Nelson KB. The volume of the sella turcica. American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine 1962 87 989-1008.
17. Lundin P & Pedersen F. Volume of pituitary macroadenomas: assessment by MRI. Journal of Computer Assisted Tomography 1992 16 519-528.
18. Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ & Gagel RF. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology 2008 159 517-523.
19. Marazuela M, Dauden E, Ocon E, Moure D & Nattero L. Pegvisomant-induced lipohypertrophy: report of a case with histopathology. Annals of Internal Medicine 2007 147 741-743.
20. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
21. Stewart PM, Stewart SE, Clark PM & Sheppard MC. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clinical Endocrinology 1999 50 295-299.
22. Peacey SR, Toogood AA, Veldhuis JD, Thorner MO & Shalet SM. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. Journal of Clinical Endocrinology and Metabolism 2001 86 259-266.
23. Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z & Strasburger CJ. Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. Journal of Clinical Endocrinology and Metabolism 2002 87 5737-5745.
24. Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G & Trainer PJ. Pegvisomant interference in GH assays results in underestimation of GH levels. European Journal of Endocrinology 2007 156 315-319.
25. Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM & Trainer PJ. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clinical Endocrinology 2002 57 59-64.
26. Hattori N, Kurahachi H, Ikekubo K, Ishihara T, Moridera K, Hino M, Saiki Y & Imura H. Effects of sex and age on serum GH binding protein levels in normal adults. Clinical Endocrinology 1991 35 295-297.
27. Bulow B, Ahren B, Fisker S, Dehlin O, Hagberg B, Jensen E, Svensson T, Samuelsson G & Erfurth EM. The gender differences in growth hormone-binding protein and leptin persist in 80-year-old men and women and is not caused by sex hormones. Clinical Endocrinology 2003 59 482-486.
28. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ & Ho KK. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. Journal of Clinical Endocrinology and Metabolism 2001 86 1716-1723.
29. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ & Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2005 90 5684-5691.
30. Rose DR & Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Hormone and IGF Research 2002 12 418-424.